Lantheus Expands Cancer Pipeline with $35M Acquisition of RM2 Rights
Portfolio Pulse from Benzinga Newsdesk
Lantheus Holdings, Inc. (NASDAQ:LNTH) has acquired global rights to Life Molecular Imaging's RM2, a radiotherapeutic and radiodiagnostic pair targeting the gastrin-releasing peptide receptor (GRPR), for $35 million. This acquisition enhances Lantheus' cancer pipeline, particularly in prostate and breast cancer.
June 27, 2024 | 11:10 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Lantheus Holdings has acquired global rights to Life Molecular Imaging's RM2 for $35 million, enhancing its cancer treatment pipeline, particularly in prostate and breast cancer.
The acquisition of RM2 rights significantly strengthens Lantheus' position in the cancer treatment market, particularly for prostate and breast cancer. This strategic move is likely to be viewed positively by investors, potentially driving the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100